Talphera Inc
NASDAQ:TLPH

Watchlist Manager
Talphera Inc Logo
Talphera Inc
NASDAQ:TLPH
Watchlist
Price: 0.9999 USD -1% Market Closed
Market Cap: $46.6m

Net Margin

-44 242.9%
Current
Declining
by 30 994.3%
vs 3-y average of -13 248.5%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-44 242.9%
=
Net Income
$-12.4m
/
Revenue
$28k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-44 242.9%
=
Net Income
$-12.4m
/
Revenue
$28k

Peer Comparison

Country Company Market Cap Net
Margin
US
Talphera Inc
NASDAQ:TLPH
45.6m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
F:1PK
5.1B EUR
Loading...
US
Johnson & Johnson
NYSE:JNJ
529.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
269.1B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.8B USD
Loading...

Market Distribution

Lower than 99% of companies in the United States of America
Percentile
1st
Based on 15 072 companies
1st percentile
-44 242.9%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Talphera Inc
Glance View

Market Cap
46.6m USD
Industry
Pharmaceuticals

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The company is headquartered in San Mateo, California and currently employs 19 full-time employees. The company went IPO on 2011-02-11. The firm is focused on the development and commercialization of therapies for use in medically supervised settings. The firm's nafamostat product candidates include Niyad and LTX-608. Niyad is focused on developing regional anticoagulants for injection into the extracorporeal circuit, such as the dialysis circuit during continuous renal replacement therapy (CRRT) for acute kidney injury (AKI) patients in the hospital, and for chronic kidney disease patients undergoing intermittent hemodialysis (IHD) in dialysis centers. LTX-608 is nafamostat formulation for direct intravenous (IV) infusion that shall be investigated and developed as a potential anti-viral for the treatment of COVID, acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), and acute pancreatitis. The firm is also engaged in developing two pre-filled syringes, namely Fedsyra and PFS-02.

TLPH Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-44 242.9%
=
Net Income
$-12.4m
/
Revenue
$28k
What is Talphera Inc's current Net Margin?

The current Net Margin for Talphera Inc is -44 242.9%, which is below its 3-year median of -13 248.5%.

How has Net Margin changed over time?

Over the last 3 years, Talphera Inc’s Net Margin has decreased from 2 391.5% to -44 242.9%. During this period, it reached a low of -44 242.9% on Oct 30, 2025 and a high of 14 440% on Mar 31, 2023.

Back to Top